Therapeutic options for a patient with mCRPC after ADT + docetaxel

An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate cancer, such as abiraterone (ABI) based on COU-AA-301 and enzalutamide (ENZA) based on AFFIRM.

EP: 1.Case presentation: Patient with metastatic CRPC after ARPI and docetaxel for localized PC

Now Viewing

EP: 2.Therapeutic options for a patient with mCRPC after ADT + docetaxel

Video content above is prompted by the following:

What are the therapeutic options included in the NCCN guidelines for this patient (eg, ABI, ENZA)? For example:

• ABI / COU-AA-301
• ENZA / AFFIRM

Recent Videos